




The relative strengths and weaknesses of Revance Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Revance Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 147% points. The greatest weakness of Revance Therapeutics Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 374%, being 120% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	172,731
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,236
Liabilities, Non-Current	0
Other Assets	464
Other Compr. Net Income	0
Other Expenses	12,823
Other Liabilities	5,864
Other Net Income	1,956
Other Revenues	383
Property and Equipment	19,274
Research and Development	33,390
Selling, General and Administrative Expense	19,043

Output Variable	Value in 1000 USD
Assets	192,469
Liabilities	16,100
Expenses	65,256
Revenues	383
Stockholders Equity	176,369
Net Income	-62,917
Comprehensive Net Income	-62,917
BaseVar	138,082
ECR before Limited Liability	308%
Economic Capital Ratio	374%